Australia markets closed

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.2200+0.1000 (+3.21%)
At close: 04:00PM EDT
3.3500 +0.13 (+4.04%)
After hours: 07:47PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 366.69M
Enterprise value 162.37M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)27.17
Price/book (mrq)0.92
Enterprise value/revenue 13.18
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.84
52-week change 382.95%
S&P500 52-week change 332.65%
52-week high 38.8300
52-week low 31.6300
50-day moving average 33.8110
200-day moving average 34.7174

Share statistics

Avg vol (3-month) 31.6M
Avg vol (10-day) 3939.16k
Shares outstanding 5113.88M
Implied shares outstanding 6113.88M
Float 890.26M
% held by insiders 12.17%
% held by institutions 1108.52%
Shares short (13 Sept 2024) 415.04M
Short ratio (13 Sept 2024) 412.51
Short % of float (13 Sept 2024) 415.16%
Short % of shares outstanding (13 Sept 2024) 413.21%
Shares short (prior month 15 Aug 2024) 413.93M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 June 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-665.73%

Management effectiveness

Return on assets (ttm)-20.50%
Return on equity (ttm)-42.10%

Income statement

Revenue (ttm)12.32M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)625.80%
Gross profit (ttm)N/A
EBITDA -163.44M
Net income avi to common (ttm)-175.72M
Diluted EPS (ttm)-1.7000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)304.88M
Total cash per share (mrq)2.68
Total debt (mrq)100.56M
Total debt/equity (mrq)25.33%
Current ratio (mrq)9.18
Book value per share (mrq)3.49

Cash flow statement

Operating cash flow (ttm)-140.57M
Levered free cash flow (ttm)-66.67M